Through integrative multiomics profiling, we identified tumor necrosis factor receptor superfamily member 1A (<i>TNFRSF1A</i>) as a key prognostic determinant associated with predicted R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) resistance, specifically localizing its expression to tumor-associated macrophages (TAMs). This evidence concerns the gene TNFRSF1A and neoplasm.